Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of ABBV-399 (Process II) in Patients with
c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer
S1400K will be temporarily closed to accrual 10/18/18 based on additional review of the safety data.
At a planned interim analysis, the study team reviewed patient data to date and did not find that every 3-week dosing of ABBV-399 was sufficiently active to continue enrolling patient to the study. S1400K will be permanently closed, on 12/21/18, to accrual based on the results.
(See required screening study SWOG S1400)